Trial Profile
A Phase 1 Study of IMC-11F8 in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2017
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 06 Apr 2012 Actual patient number changed from 14 to 15 as reported by ClinicalTrials.gov.
- 06 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.